Cullgen’s oncology portfolio features TRK, GSPT1 and CDK2 degraders.
ApexOnco Front Page
Recent articles
But now it must show that varseta-M can move into a registrational trial.
Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
JSKN027 will become the first ADC with this mechanism to enter human trials.
BeOne terminates a MUC1-targeting project.
A binary Xpovio catalyst is set for March.
Welireg, Padcev, and a surprise fillip for Flare.
Two new pivotal Chinese first-line trials have started in lung cancer.
